Year: 2017
Type: article
Study design: Observational Study
Abstract: Treatment of Alopecia Areata With TofacitinibTofacitinib citrate is a Janus kinase 1/3 inhibitor approved for the treatment of rheumatoid arthritis, but it has recently been used to treat alopecia areata (AA).[1][2][3] In this study, investigators searched the medical records of the Cleveland Clinic for any patients with confirmed AA who were treated with oral tofacitinib (Xeljanz; Pfizer) using a standardized, systematic treatment regimen.
Source: JAMA Dermatology
Institution: Cleveland Clinic
Language: English
Topic: Hair Growth and Disorders
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2602000480
